TZIANABOS ARTHUR 4
4 · Stoke Therapeutics, Inc. · Filed Feb 15, 2024
Insider Transaction Report
Form 4
TZIANABOS ARTHUR
DirectorInterim Executive Chair
Transactions
- Exercise/Conversion
Common Stock
2024-02-13$2.19/sh+31,739$69,508→ 31,739 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-13−31,739→ 0 totalExercise: $2.19Exp: 2028-12-12→ Common Stock (31,739 underlying)
Footnotes (1)
- [F1]This fully-vested option award vested as to 1/48th of the total award on October 4, 2018 with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.